Status:
COMPLETED
Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections
Lead Sponsor:
University Hospital Muenster
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Cross Infection
Staphylococcal Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly includin...
Detailed Description
In a past study, we showed that there is a strong correlation between strains colonizing the anterior nares, strains isolated from the presumed foci of infection, and strains isolated from blood in pa...
Eligibility Criteria
Inclusion
- All patients admitted to selected units in clinics for anaesthesiology, hemato-oncology, cardiac surgery, and orthopedics at the University Hospital of Muenster (following information on the study and agreement of the patient).
Exclusion
- Patients infected with S. aureus at admission
- S. aureus infection within 48 hours following admission
- Patients detected to be carrier of Methicillin-resistant S. aureus
- Hospital stay shorter than 72 hours
- Patients with anatomic abnormalities in the anterior nares
- Allergy or hypersensitivity to mupirocin or other substances of the nasal ointment
- Persons younger than 18 years
- Known pregnancy
- Persons with psychiatric diseases
- Persons with limited contractual capability and judiciousness
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT00156377
Start Date
November 1 2002
Last Update
May 25 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Medical Microbiology, University Hospital of Muenster
Münster, Germany, 48149